Tumour Angiogenesis

Summary

Our research group at the ProCURE Program (Catalan Institute of Oncology) and OncoBell Program (IDIBELL) is focused on determining the consequences of adaptation and resistance to anti-angiogenic cancer therapy. For that we use translational research in murine models of cancer, particularly Kindey Cancer PDOX models and NeuroEndocrine transgenic models to study in vivo mechanisms of adaptation to anti-angiogenics, and validate our findings using clinical samples from our hospital and collaborating institutions.
Our scientific achievements have been published in prestigious journals in the field of cancer research with numerous "preview", "highlight" or commentary articles in high impact scientific journals. Furthermore, we have an important international position in the field of antitumor therapies and angiogenic resistance mechanisms.

144 Publications

Strategic lines

Selected Publications

Peix,F;Casanovas,O, Promalignant effects of antiangiogenics in the tumor microenvironment., Semin. Cancer Biol., 2022;86(Pt 3):199-206, doi:10.1016/j.semcancer.2022.03.003

Sánchez Guixé,M;Hierro,C;Jiménez,J;Viaplana,C;Villacampa,G;Monelli,E;Brasó Maristany,F et al, High FGFR1-4 mRNA expression levels correlate with response to selective FGFR inhibitors in breast cancer., Clin. Cancer Res., 2022;28(1):137-149, doi:10.1158/1078-0432.CCR-21-1810

Selected Projects

20MEC018. Targeteando la Coagulación en la formación de metástasis en cáncer renal. Ministerio de Ciencia e Innovación. Budget: 145200. 2020-2023. PI: Casanovas Casanovas, Oriol.

20MAR004. Identification of Kidney Cancer progression targets and biomarkers through CRISPRengineered organoids and xenograft mouse models. Fundació La Marató de TV3. Budget: 136250. 2020-2023. PI: Casanovas Casanovas, Oriol.

AEC21003. Angiotheragnostics (AtG): Developing a First-in-Class anticancer treatment with its patient selection biomarker for patients with advanced kidney cancer. Asociación Española Contra el Cáncer (AECC). Budget: 180000. 2021-2023. PI: Casanovas Casanovas, Oriol.

FIS21102. ANGIOTHERAGNOSTICS: DESARROLLO DE UN NUEVO TRATAMIENTO CON SU BIOMARCADOR DE SELECCIÓN DE PACIENTES PARA PACIENTES CON CÁNCER COLORECTAL AVANZADO. Instituto de Salud Carlos III (ISCIII). Budget: 149600. 2022-2023. PI: Casanovas Casanovas, Oriol.

MCI21016. Desarrollo de un nuevo biomarcador y su 'kit' prototipo para predecir la Respuesta Agresiva en Cancer. Ministerio de Ciencia e Innovación. Budget: 132250. 2021-2023. PI: Casanovas Casanovas, Oriol.

Technology transfer

PAT041: “PD-ECGF AS BIOMARKER OF CANCER”
IP: Oriol Casanovas
EP15382109

PAT080-"METHODS FOR PREDICTING THE RISK OF LOCAL INVASION AND/OR METASTASIS INDUCED BY AN ANTIANGIOGENIC TREATMENT"
IP: Oriol Casanovas
EP20382600

PAT088: PYRIMIDINE-1,3-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF
CANCER
IP: Oriol Casanovas
EP23382217

License: PD- ECGF AS BIOMARKER OF CANCER
PI: Dr. Oriol Casanovas

Spin-off: AtG Therapeutics
PI: Dr. Oriol Casanovas

More Information

2015 Proof of Concept (PoC) grant from the European Research Council – Oriol Casanovas.

Mapping the pathogenesis of vascular malformations
IP: Graupera Garcia-Mila, Mariona (Project Leader)
Partners: Centro Nacional de Investigaciones Cardiovasculares-CNIC (Dr. R. Benedito), Hospital Santa Creu Sant Pau (Dra. E. Baselga) i Sant Joan de Déu (Dr. J. Mora)
Call: Health Research 2018 Call for proposals, expediente: HR18-00120
Funding Entity: Fundació “la Caixa”